関連する実験動画
Updated: May 12, 2026

14:19
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
急性心筋梗塞におけるロングペントラキシンPTX3の心臓保護機能
Monica Salio1, Stefano Chimenti, Noeleen De Angelis
1Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Circulation
|February 13, 2008
まとめ
ロングペントラキシンPTX3は,急性心筋梗塞時に心臓を保護します. PTX3欠乏症のマウスは,心臓損傷の悪化を示し,その重要な心臓保護作用を示した.
科学分野:
- バイオメディカル研究
- 心血管科学 心血管科学
- 炎症と免疫学について
背景:
- C反応性タンパク質は,缺血性心疾患の予後マーカーであるが,種の違いにより遺伝的検証が欠けている.
- 長いペントラキシンPTX3は進化的に保存され,炎症時に心臓で発現します.
- PTX3は,急性心筋梗塞 (AMI) の潜在的な予後マーカーです.
研究 の 目的:
- 急性心筋梗塞におけるPTX3の病原遺伝的役割を調査する.
- PTX3がAMIの文脈で保護的機能を持っているかどうかを判断する.
主な方法:
- 冠動脈連結と再注血によって誘発されたAMIのマウスモデルを使用しました.
- 評価されたPTX3発現と血中不全後のレベル.
- PTX3欠乏症 (ptx3-nullマウス) が心臓損傷に及ぼす影響を研究した.
- フェノタイプを救うために外因的なPTX3を投与した.
主要な成果:
- PTX3発現と循環レベルは,AMI後に増加した.
- PTX3欠乏症は,著しく大きな心臓発作 (33%増加) と悪化した心臓損傷をもたらしました.
- PTX3の欠乏は,中性粒子の浸透の増加,毛細血管の密度の低下,およびより高い心筋細胞アポトーシスと関連していました.
- PTX3欠乏したマウスは,インタールイキン-6とコンプリメントC3の堆積量が増加した.
- 外因的なPTX3投与は,ptx3-nullマウスで観察された有害な効果を逆転させた.
結論:
- PTX3はAMIにおける重要な,非冗余的,および規制性心臓保護的役割を果たします.
- AMIにおけるPTX3の保護機能には,補完カスケードの調節が含まれます.
関連する概念動画
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

